Macular Degeneration – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Macular degeneration, an age-related retinal disease, is characterized by a gradual central visual acuity decline, primarily due to neovascularization in the subretinal space, partly driven by vascular endothelial growth factor (VEGF) activity. In its early stages, macular degeneration can manifest subtly:
1. Gradual loss of clear object perception
2. Objects may seem distorted in shape
3. Straight lines can appear wavy or irregular
4. A diminished ability to perceive colors distinctly
5. Development of a dark or empty spot at the center of one’s vision
The underlying causes of macular degeneration remain unidentified. Notably, women tend to experience AMD earlier than men. This condition occurs in two forms: “dry” (atrophic) and “wet” (exudative), with the majority of cases falling into the dry category. Unfortunately, no specific treatment exists for dry AMD. However, recent advancements have introduced various agents targeting VEGF, which have shown promise in slowing the progression of neovascular or “wet” macular degeneration when administered via intravitreal injections. These agents include monoclonal antibodies to VEGF (such as bevacizumab and ranibizumab), aptamers (small oligonucleotides binding to VEGF, like pegaptanib), and fusion VEGF receptor proteins acting as decoys for the circulating growth factor (e.g., aflibercept). The primary risk factor for macular degeneration is age, with a higher prevalence among those with a family history, Caucasians, and smokers. Women are more susceptible to age-related macular degeneration, and additional risk factors include high blood pressure, high cholesterol, heart disease, light-colored irises, sun exposure, farsightedness, and a diet lacking in fish.
• Approximately 19.8 million Americans aged 40 and above, accounting for 12.6% of the population, were estimated to be living with age-related macular degeneration (AMD).

Thelansis’s “Macular Degeneration Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Macular Degeneration treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Macular Degeneration across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Macular Degeneration Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Macular Degeneration – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033